Get the Stockscreener App
31.85
0.19%
0.06
Pre-market:
32.48
0.63
+1.98%
Mbx Biosciences Inc stock is traded at $31.85, with a volume of 436.08K.
It is up +0.19% in the last 24 hours and down -5.15% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
See More
Previous Close:
$31.79
Open:
$31.91
24h Volume:
436.08K
Relative Volume:
0.75
Market Cap:
$1.52B
Revenue:
-
Net Income/Loss:
$-86.97M
P/E Ratio:
-13.17
EPS:
-2.4189
Net Cash Flow:
$-81.88M
1W Performance:
-1.85%
1M Performance:
-5.15%
6M Performance:
+17.61%
1Y Performance:
+154.60%
1-Day Range:
$31.21
$32.89
1-Week Range:
$29.60
$33.11
52-Week Range:
$9.43
$45.85
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
31.85 | 1.51B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Dec-04-25 | Initiated | Goldman | Sell |
| Nov-04-25 | Initiated | TD Cowen | Buy |
| Oct-15-25 | Initiated | Truist | Buy |
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
MBX Technical Analysis | Trend, Signals & Chart Patterns | MBX BIOSCIENCES INC (NASDAQ:MBX) - ChartMill
MBX Biosciences, Inc. thanks clinical trial participants as new therapies progress - Traders Union
MBX Biosciences (MBX) price target increased by 11.23% to 69.55 - MSN
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $91 - Moomoo
Insider Stock Buying Reaches US$1.06m On MBX Biosciences - Yahoo Finance
MBX Biosciences Advances Obesity And PBH Pipeline As Shares Surge - Sahm
Insider sale notice: 15,000 shares planned | MBX SEC FilingForm 144 - Stock Titan
Analysts Offer Insights on Healthcare Companies: Radnet (RDNT) and MBX Biosciences, Inc. (MBX) - The Globe and Mail
MBX Biosciences (NASDAQ:MBX) Trading Down 8.8%Here's What Happened - MarketBeat
A Quick Look at Today's Ratings for MBX Biosciences(MBX.US), With a Forecast Between $56 to $86 - Moomoo
AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements - Benzinga
MBX Biosciences (NASDAQ:MBX) Price Target Raised to $86.00 at Citizens Jmp - MarketBeat
Q2 EPS Estimates for MBX Biosciences Boosted by Analyst - MarketBeat
Citizens raises MBX Biosciences stock price target on obesity drug data By Investing.com - Investing.com South Africa
Citizens raises MBX Biosciences stock price target on obesity drug data - Investing.com Nigeria
MBX Biosciences stock hits all-time high at 44.98 USD By Investing.com - Investing.com India
MBX Biosciences reports early obesity drug trial data By Investing.com - Investing.com Australia
Stifel raises MBX Biosciences stock price target to $56 on obesity data - Investing.com UK
MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics PortfolioSlideshow (NASDAQ:MBX) 2026-05-11 - Seeking Alpha
Stifel raises MBX Biosciences stock price target to $56 on obesity data By Investing.com - Investing.com South Africa
MBX highlights early data for monthly obesity drug MBX-4291 - BioWorld News
Mbx Biosciences Insider Sold Shares Worth $2,685,515, According to a Recent SEC Filing - marketscreener.com
MBX Biosciences (MBX) CMO exercises options and sells 70,003 shares under 10b5-1 plan - Stock Titan
MBX (NASDAQ) affiliate sells multiple tranches of shares in Rule 144 notices - Stock Titan
MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push - MarketBeat
MBX: MBX 4291 achieves 7% mean weight loss with strong tolerability in phase I, supporting monthly dosing - TradingView
Insiders Of MBX Biosciences Are Up 125% On Their US$1.06m Purchase - Moomoo
MBX Biosciences (NASDAQ:MBX) Price Target Raised to $70.00 - MarketBeat
MBX Biosciences Reports Positive Phase 1 Results for Once-Monthly Obesity Drug MBX 4291 and Expands Obesity Pipeline - Minichart
MBX: MBX's obesity pipeline advances with promising once-monthly candidates and strong financial runway - TradingView
MBX Biosciences : May 2026 Obesity Day Presentation – Final - marketscreener.com
MBX Biosciences stock hits all-time high at 44.98 USD - Investing.com
Obesity portfolio update features new clinical data from MBX Biosciences, Inc. - Traders Union
MBX Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Truist Raises Price Target on MBX Biosciences to $70 From $50, Keeps Buy Rating - marketscreener.com
MBX Biosciences Highlights Positive Phase 1 Obesity Data - TipRanks
MBX Biosciences reports early obesity drug trial data - Investing.com
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing - The Manila Times
MBX Biosciences, Inc. Provides Obesity Portfolio Update Including Initial Phase 1 Data For MBX 4291 Supporting Potential For Once-Monthly Dosing - marketscreener.com
Brokers Set Expectations for MBX Biosciences Q1 Earnings - MarketBeat
A Look At MBX Biosciences (MBX) Valuation After Its Recent Share Price Momentum - Sahm
Wall Street Zen Upgrades MBX Biosciences (NASDAQ:MBX) to Hold - MarketBeat
MBX SEC FilingsMBX Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Top MBX Biosciences Executive Makes Notable Stock Move - TipRanks
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):